Valuable research was also presented by Lee et al., who demonstrated the richness of the microbiome in Bifidobacterium bifidum in a group of NSCLC patients with a better response to anti-PD-L1 treatment [72]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.